METHOD OF TREATING CANCER USING COMBINATION OF BRAF INHIBITOR, MEK INHIBITOR, AND ANTI-CTLA-4 ANTIBODY

摘要

A combination of anti-neoplastic agents that provides increased activity over monotherapy. In particular, the drug combination that includes an anti-CTLA-4 antibody, in combination with the B-Raf inhibitor N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and MEK inhibitor N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide, or a pharmaceutically acceptable salt or solvate thereof is described.